Research powered investment banking
Home
Research
Companies
Themes
Top Picks
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
Posts
Investor Scoring
sign in
Member sign in
Join redeye
Home
research
Companies
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
community
Posts
Investor Scoring
The latest from Redeye about Scandinavian Life Science and Technology companies
Xbrane Biopharma
Fyller på kassan
Xvivo Perfusion
Collaboration to develop diagnostic tool
Arise
Klent resultat men starkt kassaflöde
Xbrane Biopharma
Ett bet på biosimilarer
Sdiptech
Q2’19 Preview
Mycronic
Q2’19: Stark orderingång
Bong
Declining top-line calls for action
Ericsson
Bra inom Networks, men svag i övrigt
Alelion Energy Systems
High uncertainty, high potential
Northbaze/Jays Group
Sound of a turnaround
IRLAB Therapeutics
Våra reflektioner och insikter kring fas IIa-resultaten
Addnode Group
Q2’19 Preview
Orexo
Intervju med vd Nikolaj Sørensen (video)
Events
07
Aug
ENLABS: Quarterly Report Presentation and Q&A (English)
20
Aug
Immunicum: Quarterly Report Presentation & Business Strategy Review (English)
21
Aug
IMINT: Live Quarterly Presentation and Q&A (Swedish)
28
Aug
Cancer Imaging Lunch
29
Aug
Investor Lunch
06
Sep
Mycronic: Investor Lunch
Announcements
New accounting principle to affect upcoming interim reports
Redeye söker Projektledare inom Corporate Finance
Redeye sponsrar integrationsprojektet Näringslivet Möter Förorten